General Mills' organic business already delivers 61% more revenue annually than Annie's. Where's the value in this acquisition?
Seadrill shares should command a fair market value of $40 in the next 12 to 18 months.
Now is the perfect time for investors to buy GE shares.
Who cares about J&J's sluggish medical devices business when it has such a strong drug pipeline and balance sheet?
These shares are still too expensive for new investors.
Allergan's management and its board are right to resist Bill Ackman's bid and protect the interest of shareholders.
Wall Street is wrong to discount Baxter's value-creating potential.
The company has a potential life-saving catalyst in its portfolio, too.
There's no compelling reason to buy this stock above $40.
The market seems divided on where the company is heading next.